SAN
JOSE, Calif., Sept. 3,
2024 /PRNewswire/ -- Anixa Biosciences,
Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a
biotechnology company focused on the treatment and prevention of
cancer, today announced that the inventor of its ovarian cancer
CAR-T technology, Jose R.
Conejo-Garcia, M.D., Ph.D., Professor of Immunology in the
Department of Integrative Immunobiology at the Duke University School of Medicine, will be
speaking at the Rivkin Center and American Association for Cancer
Research (AACR) 15th Biennial Ovarian Cancer Research Symposium.
Dr. Conejo-Garcia will be giving the opening keynote address on
Friday, September 20, 2024.
During the keynote address, Dr. Conejo-Garcia will discuss
Anixa's chimeric antigen receptor-T cell (CAR-T) technology, which
is an autologous cell therapy comprised of engineered T cells that
target the follicle stimulating hormone receptor (FSHR). FSHR is
found at immunologically relevant levels exclusively on the
granulosa cells of the ovaries. Since the target is a hormone
(chimeric endocrine) receptor, and the target-binding domain is
derived from its natural ligand, this technology is known as CER-T
(chimeric endocrine receptor-T cell) therapy, a new type of CAR-T.
Anixa holds an exclusive world-wide license to the technology from
The Wistar Institute. Dr. Conejo-Garcia will also discuss the
ongoing Phase 1 clinical trial of this technology.
"I am pleased to discuss this novel FSHR-mediated CAR-T
technology at the Ovarian Cancer Research Symposium and to share
ideas and advance the field of ovarian cancer research," stated Dr.
Conejo-Garcia. "Anixa and its development partner, Moffitt Cancer
Center, have been working together to advance this ovarian cancer
therapy and we are excited about the clinical results to date—with
the treatment appearing to be safe and well-tolerated, and some
patients exhibiting tumor necrosis. If this therapeutic approach is
successful, this could enable a major shift in the overall
treatment paradigm for ovarian cancer."
More information about the event may be found at:
https://rivkin.org/symposia/ocrs/.
About Anixa Biosciences, Inc.
Anixa is a
clinical-stage biotechnology company focused on the treatment and
prevention of cancer. Anixa's therapeutic portfolio consists of an
ovarian cancer immunotherapy program being developed in
collaboration with Moffitt Cancer Center, which uses a novel type
of CAR-T, known as chimeric endocrine receptor-T cell (CER-T)
technology. The Company's vaccine portfolio includes vaccines being
developed in collaboration with Cleveland Clinic to prevent breast
cancer – specifically triple negative breast cancer (TNBC), the
most lethal form of the disease – and ovarian cancer, as well as
additional cancer vaccines to address many intractable cancers,
including high incidence malignancies in lung, colon, and prostate.
These vaccine technologies focus on immunizing against "retired"
proteins that have been found to be expressed in certain forms of
cancer. Anixa's unique business model of partnering with
world-renowned research institutions on all stages of development
allows the Company to continually examine emerging technologies in
complementary fields for further development and commercialization.
To learn more, visit www.anixa.com or follow Anixa on Twitter,
LinkedIn, Facebook and YouTube.
Forward-Looking Statements
Statements that are not historical fact may be considered
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements are not statements of historical facts, but rather
reflect Anixa's current expectations concerning future events and
results. We generally use the words "believes," "expects,"
"intends," "plans," "anticipates," "likely," "will" and similar
expressions to identify forward-looking statements. Such
forward-looking statements, including those concerning our
expectations, involve risks, uncertainties and other factors, some
of which are beyond our control, which may cause our actual
results, performance or achievements, or industry results, to be
materially different from any future results, performance, or
achievements expressed or implied by such forward-looking
statements. These risks, uncertainties and factors include, but are
not limited to, those factors set forth in "Item 1A - Risk Factors"
and other sections of our most recent Annual Report on Form 10-K as
well as in our Quarterly Reports on Form 10-Q and Current Reports
on Form 8-K. We undertake no obligation to publicly update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise, except as required by law.
You are cautioned not to unduly rely on such forward-looking
statements when evaluating the information presented in this press
release.
Contact:
Mike Catelani
President, COO & CFO
mcatelani@anixa.com
408-708-9808
View original content to download
multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-announces-presentation-on-its-ovarian-cancer-car-t-therapy-at-the-rivkin-center-aacr-15th-biennial-ovarian-cancer-research-symposium-302233678.html
SOURCE Anixa Biosciences, Inc.